LCID
Lucid Group, Inc.
LCID lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
OCG
Oriental Culture Holding Ltd.
There isn't enough reported data to score OCG yet.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
OCG Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
OCG's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
OCG PE Valuation
OCG has no meaningful PE right now: it lost money over the past year.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OCG Forward outlook
There aren't enough analyst estimates for OCG to show an outlook.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
OCG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$107.26 | +$11.54 |
| Q4 2024 | -$118.80 | +$435.60 |
| Q4 2023 | -$554.40 | -212% |
OCG has the edge over LCID in the latest year-over-year earnings comparison.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over OCG in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
OCG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $1.9M | +203% |
| Q4 2024 | $622.7K | -61% |
| Q4 2023 | $1.6M | -91% |
| Q4 2022 | $17.8M | -53% |
| Q4 2021 | $37.6M | +116% |
| Q4 2020 | $17.4M | +212% |
| Q4 2019 | $5.6M | +4.6% |
OCG's revenue has slid since its 2021 peak: $2M last quarter, down 95% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -203% | -232 points |
| Q4 2024 | -513% | -523 points |
| Q4 2023 | -274% | -322 points |
| Q4 2022 | 15% | -66 points |
| Q4 2021 | 29% | -21 points |
| Q4 2020 | 9.4% | N/A |
| Q4 2019 | 48% | N/A |
| Q2 2019 | 80% | N/A |
OCG's operating margin was −203% last quarter, down 232 points from the same quarter a year ago.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
OCG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$4.1M | -218% |
| Q4 2023 | $3.4M | +$5.4M |
| Q4 2022 | -$1.9M | -$1.3M |
| Q4 2021 | -$573.5K | -107% |
| Q4 2020 | $8.1M | +302% |
| Q4 2019 | $2M | -36% |
| Q2 2019 | $7.3M | +9184% |
| Q4 2018 | $3.1M | +7928% |
OCG's free cash flow has turned negative after years in the green: −$3M over the past year.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has the edge over OCG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
OCG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +79% | +15.9K shares |
| 1 year | +479% | +29.8K shares |
OCG has 35,968 diluted shares, up 479% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
| Q2 2019 | — |
| Q4 2018 | $125 |
| Q2 2018 | — |
| Q4 2017 | — |
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OCG Net Leverage
OCG's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
OCG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.6 | Oversold |
| Stochastic | 30.4 | Neutral |
OCG's weekly RSI is 25 (oversold) and its Stochastic is 30 (neutral).
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
OCG PE vs Consumer Cyclical Sector
| Metric | OCG | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
OCG has no meaningful PE right now: it lost money over the past year.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
OCG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.63 | 0.6% below |
| 20 week MA | $1.64 | 1.2% below |
| 50 week MA | $46.0 | 96% below |
| 100 week MA | $1,165.0 | 100% below |
| 200 week MA | $1,218.6 | 100% below |
OCG is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has the edge over OCG on returns for 2026, with the stronger performance.
OCG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19,800.0 | $17,886.0 | -9.7% |
| 2021 | $17,886.0 | $16,632.0 | -7% |
| 2022 | $16,632.0 | $1,881.0 | -89% |
| 2023 | $1,881.0 | $943.8 | -50% |
| 2024 | $943.8 | $772.2 | -18% |
| 2025 | $772.2 | $56.8 | -93% |
| 2026 YTD | $56.8 | $1.62 | -97% |
OCG has finished every year since 2020 lower, and it's down 97% so far in 2026.